Printer Friendly

NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS

 NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
 MIAMI, March 5 /PRNewswire/ -- North American Biologicals, Inc. (NABI) (NASDAQ: NBIO) today announced fiscal year 1991 results.
 For the year ended Dec. 31, 1991, the company reported sales of $68,230,000 and pretax earnings of $3,053,000, compared to $72,822,000 and $3,002,000, respectively, in 1990. Net income for 1991 was $2,217,000, or 14 cents per share, compared with $2,338,000, or 15 cents per share in the prior year. Results for 1990 included extraordinary tax credits of $203,000, or 1 cent per share.
 NABI management noted three key aspects of the company's 1991 performance. "We are, first of all, very pleased with the company's success this year in sustaining last year's record operating profits, which we attribute to our successful strategy in shifting the product mix towards increasingly sophisticated and profitable plasma-based products. We intend to continue this approach to enhance profitability," said David J. Gury, president of NABI.
 "Secondly, a major issue which contributed to softness in demand for plasma products during 1991 -- the difference in testing requirements between European and U.S. regulatory agencies -- has been favorably resolved for NABI. Consequently, we have enjoyed rising demand for plasma products since October 1991, as reflected by fourth quarter sales of $18,452,000, compared to $17,384,000 in the prior year. This upswing represents a strong positive indicator for the future," Gury added.
 "Thirdly, 1991 was a year in which NABI's leadership in the field of AIDS testing was realized, with the awarding of additional federal contracts for military testing as well as the very promising launch of our unique QC-HIV(tm) Diagnostic Reagent for ensuring accuracy of HIV testing in laboratories worldwide. We anticipate a continued trend towards increased AIDS testing as part of the international effort to stem the spread of this disease," he said.
 North American Biologicals, Inc. is the world's largest independent provider of human blood plasma elements to the health care industry, the largest AIDS screening laboratory in the United States, and the leading supplier of control products used to ensure accuracy in blood testing laboratories.
 NORTH AMERICAN BIOLOGICALS, INC.
 SELECTED CONSOLIDATED FINANCIAL DATA
 ($ Thousands, Except Per Share Amounts)
 For The Years Ended
 Dec. 31,
 1991 1990
 Net sales $68,230 $72,822
 Income before provision for
 income taxes and
 extraordinary credit $3,053 $3,002
 Provision for income taxes 836 790
 Income before
 extraordinary credit 2,217 2,212
 Extraordinary credit(a) --- 126
 Net income $2,217 $2,338
 Earnings per share:
 Income before extraordinary
 credit 14 cents 14 cents
 Extraordinary credit --- 1 cent
 Net income 14 cents 15 cents
 Weighted average shares and
 common share equivalents 15,980 15,587
 ----
 NOTE: Extraordinary credit reflects utilization of general business credit carryforwards in 1990.
 -0- 3/5/92
 /CONTACT: David J. Gury, president, or Alfred J. Fernandez, vice president of finance, of North American Biologicals, 305-628-0080; or Marcia A. Kean of Feinstein Partners, 617-577-8110, for North American Biologicals/
 (NBIO) CO: Northern American Biologicals ST: Massachusetts IN: MTC SU: ERN


EG-DD -- NE002 -- 5262 03/05/92 08:32 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 5, 1992
Words:522
Previous Article:ROSS STORES REPORTS FEBRUARY SALES
Next Article:CIRCUIT CITY STORES, INC. REPORTS FEBRUARY AND FISCAL YEAR SALES
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS, INC. REPORTS SECOND QUARTER 1992 RESULTS; SALES AND OPERATING INCOME AT RECORD LEVELS FOR QUARTER AND YEAR TO DATE
NORTH AMERICAN BIOLOGICALS, INC. ANNOUNCES THIRD QUARTER AND YEAR-END 1992 OUTLOOK
GAMMA BIOLOGICALS REPORTS EARNINGS FOR SECOND QUARTER AND SIX MONTHS
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1992 RESULTS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS FIRST QUARTER 1993 RESULTS; RETURNS TO PROFITABILITY
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD REVENUES AND PROFITS FOR 1993
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR FIRST QUARTER 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR THIRD QUARTER AND NINE MONTHS 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD PERFORMANCE FOR 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR SECOND QUARTER 1995

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters